Travere Therapeutics, Inc.
TVTXNasdaq
$56.71
↑ +2.6%Jul 17 close · end-of-day
Price
1Y↑ +240.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.2B
Enterprise Value
$5.0B
P/E
—
P/S
9.7
P/B
52.8
EV/EBITDA
310.8
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$536.2M
Net Income (TTM)
-$21.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-10.6%
Net Margin
-4.0%
ROE
-21.7%
ROIC
—
Debt / Equity
—
Net Cash
$208.9M
Return 1Y
+243.5%
Company profile
Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.
- CEO
- Eric M. Dube
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 460
- Headquarters
- California
- Website
- travere.com
Earnings
TVTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$127.2M↑ +55.6%
Diluted EPS-$0.40↓ -14.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $198.3M | $131.8M | $109.5M | $145.2M | $233.2M | $490.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$176.2M | -$199.4M | -$319.8M | -$388.1M | -$323.8M | -$62.8M |
| Net income | -$169.4M | -$180.1M | -$278.5M | -$111.4M | -$321.5M | -$25.5M |
| Diluted EPS | -$3.56 | -$3.01 | -$4.37 | -$1.50 | -$4.08 | -$0.29 |
| Operating cash flow | -$42.7M | -$14.8M | -$186.3M | -$280.0M | -$237.5M | $37.8M |
| Free cash flow | -$49.5M | -$19.9M | -$186.5M | -$280.7M | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -88.8% | -151.3% | -292.2% | -267.2% | -138.9% | -12.8% |
| Net margin | -85.4% | -136.6% | -254.4% | -76.7% | -137.9% | -5.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $54.1M | $62.9M | $74.8M | $81.7M | $114.4M | $164.9M | $129.7M | $127.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$67.7M | -$56.1M | -$60.7M | -$42.7M | -$12.7M | $24.9M | -$32.4M | -$36.9M |
| Net income | -$70.4M | -$54.8M | -$60.3M | -$41.2M | -$12.8M | $25.7M | $2.7M | -$37.1M |
| Diluted EPS | -$0.91 | -$0.70 | -$0.71 | -$0.47 | -$0.14 | $0.28 | $0.04 | -$0.40 |
| Operating cash flow | -$40.2M | -$42.5M | -$35.7M | -$42.2M | $5.0M | $14.3M | $60.7M | -$40.4M |
| Free cash flow | -$40.3M | -$42.5M | — | — | — | $14.2M | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -125.1% | -89.3% | -81.2% | -52.2% | -11.1% | 15.1% | -25.0% | -29.0% |
| Net margin | -130.1% | -87.1% | -80.6% | -50.4% | -11.1% | 15.6% | 2.1% | -29.2% |
Company news
Jul 10, 2026
Jun 16, 2026
Jun 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.